EPCT-10. DEBIO1347, AN ORAL FGFR INHIBITOR: RESULTS FROM A SINGLE CENTER STUDY IN RECURRENT/REFRACTORY FGFR ALTERED PEDIATRIC GLIOMAS

BACKGROUND: Oncogenic driver alterations in FGFR are present in a subset of pediatric gliomas. Debio1347 is an orally available, highly selective FGFR 1–3 inhibitor that had a favorable safety profile and encouraging preliminary clinical activity in an adult phase 1 study. METHODS: Five children wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Farouk Sait, Sameer, Gilheeney, Stephen, Bale, Tejus, Rosenblum, Marc, Haque, Sofia, Ibanez, Katarzyna, Dinkin, Marc, Vitolano, Stephanie, Dunkel, Ira, Karajannis, Matthias
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2021
Teme:
Translational/Early Phase Clinical Trials
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168087/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.196
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items